ロード中...
Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis
Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer (NSCLC). In this article, we updated the evidence of erlotinib in treating advanced NSCLC by adding new results of RCTs publi...
保存先:
| 出版年: | Transl Lung Cancer Res |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Pioneer Bioscience Publishing Company
2012
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4367576/ https://ncbi.nlm.nih.gov/pubmed/25806169 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2218-6751.2012.06.01 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|